Specialty pharma company Mallinckrodt plc (MNK), Friday announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application or SNDA for Acthar Gel Single-Dose Pre-Filled SelfJect Injector for the treatment of patients with inflammatory and autoimmune disorders.
The company stated that SelfJect, pre-filled with the prescribed dose of Acthar Gel in 40-unit or 80-unit versions, would be available in the U.S. in the second half of 2024.
Along with the device, the company also offers insurance coverage, commercial copay assistance, injection training services, and customized nurse assistance.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.